Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Clinical trial NCT05228015 · TERMINATED

Trial details

NCT number: NCT05228015
Sponsor: Ikena Oncology
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors, Adult Solid Tumor Malignant Pleural Mesothelioma (MPM)Epithelioid Hemangioendothelioma (EHE)NF2 Deficient Mesothelioma Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes NF2 Deficiency YAP1 or TAZ Gene Fusions

Start date: 2022-01-07
Primary completion: 2024-08-27
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.